Lior Shaltiel
Directeur Général chez NUREXONE BIOLOGIC INC.
Fortune : 158 950 $ au 31/05/2024
Profil
Dr. Lior Shaltiel is a Chief Executive Officer & Director at NurExone Biologic Ltd.
and a Chief Executive Officer & Director at NurExone Biologic, Inc. He is on the Board of Directors at NurExone Biologic Ltd.
and NurExone Biologic, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC
0,63% | 16/05/2024 | 425 000 ( 0,63% ) | 158 950 $ | 31/05/2024 |
Postes actifs de Lior Shaltiel
| Sociétés | Poste | Début |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Directeur Général | 01/04/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Directeur Général | 01/04/2021 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
